Get the Stockscreener App
64.27
0.81%
0.515
After Hours:
64.27
Soleno Therapeutics Inc stock is traded at $64.27, with a volume of 1.08M.
It is up +0.81% in the last 24 hours and up +19.86% over the past month.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
See More
Previous Close:
$63.76
Open:
$64
24h Volume:
1.08M
Relative Volume:
0.61
Market Cap:
$3.42B
Revenue:
-
Net Income/Loss:
$-38.99M
P/E Ratio:
-21.45
EPS:
-2.9966
Net Cash Flow:
$-24.94M
1W Performance:
+9.96%
1M Performance:
+19.86%
6M Performance:
-4.40%
1Y Performance:
+17.39%
1-Day Range:
$62.93
$65.50
1-Week Range:
$59.68
$66.09
52-Week Range:
$41.50
$90.32
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Name
Soleno Therapeutics Inc
Sector
Industry
Phone
650-213-8444
Address
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Compare SLNO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
64.27 | 3.39B | 0 | -38.99M | -24.94M | -2.9966 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-25 | Initiated | Goldman | Buy |
| Aug-20-25 | Initiated | Wells Fargo | Overweight |
| Jun-23-25 | Initiated | TD Cowen | Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Dec-02-24 | Reiterated | Robert W. Baird | Outperform |
| Dec-02-24 | Reiterated | Stifel | Buy |
| Sep-03-24 | Initiated | H.C. Wainwright | Buy |
| May-10-24 | Initiated | Robert W. Baird | Outperform |
| Feb-05-24 | Initiated | Piper Sandler | Overweight |
| Jan-23-24 | Initiated | Stifel | Buy |
| Nov-21-23 | Resumed | Guggenheim | Buy |
| Sep-29-20 | Initiated | Guggenheim | Buy |
| Jan-10-20 | Initiated | Craig Hallum | Buy |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
View All
Soleno Therapeutics Inc Stock (SLNO) Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc.SLNO - WV News
Has Soleno Therapeutics Inc. formed a bullish divergenceTrade Volume Report & Fast Momentum Stock Entry Tips - newser.com
Is Soleno Therapeutics Inc. stock entering bullish territoryPortfolio Risk Summary & Stock Market Timing Techniques - newser.com
Multi asset correlation models including Soleno Therapeutics Inc.July 2025 News Drivers & High Conviction Buy Zone Picks - newser.com
Will Soleno Therapeutics Inc. outperform the marketEarnings Recap Summary & Short-Term High Return Strategies - newser.com
Strategies to average down on Soleno Therapeutics Inc.Weekly Investment Recap & Fast Gain Stock Trading Tips - newser.com
Soleno Therapeutics appoints biopharma finance veteran to board - Investing.com India
Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors - GlobeNewswire
Nearly 30 Years of CFO Experience: Soleno Adds Mark W. Hahn to Board to Support VYKAT XR Launch - Stock Titan
Using Bollinger Bands to evaluate Soleno Therapeutics Inc.Weekly Market Report & Low Risk Entry Point Guides - newser.com
SLNO Investor News: If You Have Suffered Losses in Soleno - GlobeNewswire
Soleno drops on death of patient treated with Vykat XR - MSN
SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
Soleno Therapeutics stock dips on proposed $200M offering - MSN
Soleno Stock: Blockbuster Launch In Progress (NASDAQ:SLNO) - Seeking Alpha
Soleno Therapeutics (NASDAQ:SLNO) Coverage Initiated by Analysts at The Goldman Sachs Group - MarketBeat
How to use Fibonacci retracement on Soleno Therapeutics Inc.Gap Down & Fast Moving Stock Watchlists - newser.com
Published on: 2025-10-10 05:36:53 - newser.com
Can Soleno Therapeutics Inc. stock deliver sustainable ROEMarket Volume Report & Expert Curated Trade Setup Alerts - newser.com
Soleno Therapeutics (SLNO) Drops Amid Critical Scorpion Report -- Hagens Berman - GlobeNewswire
SOLENO (SLNO) REMINDER: Bragar Eagel & Squire, P.C. Reminds - GlobeNewswire
Published on: 2025-10-09 06:36:22 - newser.com
Will Soleno Therapeutics Inc. bounce back from current supportJuly 2025 Gainers & Capital Protection Trading Alerts - newser.com
What Wall Street predicts for Soleno Therapeutics Inc. stock priceAnalyst Downgrade & Weekly High Return Stock Forecasts - newser.com
How to recover losses in Soleno Therapeutics Inc. stockGap Up & Daily Oversold Bounce Ideas - newser.com
Soleno Therapeutics (NASDAQ:SLNO) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
Is Soleno Therapeutics Inc 6XC a good long term investment - earlytimes.in
Piper Sandler Maintains a Buy Rating on Soleno Therapeutics (SLNO), Sets a $145 PT - Yahoo Finance
Soleno Therapeutics (NASDAQ:SLNO) Trading Up 7%Should You Buy? - MarketBeat
Soleno Therapeutics (SLNO): Reassessing Valuation After VYKAT XR Safety Debate and Analyst Support - Yahoo Finance
Goldman Sachs Initiates Soleno Therapeutics at Buy With $125 Price Target - MarketScreener
Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock - GlobeNewswire
Goldman Sachs initiates Soleno Therapeutics stock with Buy rating on Vykat potential - Investing.com
Rosen Law Firm Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action InvestigationSLNO - Eastern Progress
Is Soleno Therapeutics Inc. stock supported by strong cash flows - newser.com
Soleno Therapeutics (SLNO) Is Down 8.9% After Short Seller Targets VYKAT XR Safety and Market Potential – Has The Bull Case Changed? - Sahm
How Soleno Therapeutics Inc. stock performs in rate cut cyclesJuly 2025 Analyst Calls & Safe Entry Point Alerts - newser.com
Detecting support and resistance levels for Soleno Therapeutics Inc.Weekly Stock Recap & Verified Entry Point Signals - newser.com
How Soleno Therapeutics Inc. (6XC) stock stacks up against competitorsMarket Performance Summary & Growth Focused Entry Reports - newser.com
Soleno Therapeutics (SLNO): Assessing Valuation and Growth Potential in the Biotech Sector - Sahm
Piper Sandler reiterates Overweight rating on Soleno Therapeutics stock - Investing.com
How to escape a deep drawdown in Soleno Therapeutics Inc.Trade Exit Summary & Weekly High Return Forecasts - newser.com
Will Soleno Therapeutics Inc. (6XC) stock justify high valuationJuly 2025 Reactions & Free Growth Oriented Trading Recommendations - newser.com
Stifel Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Cuts Target Price to $115 - 富途牛牛
What analysts say about Soleno Therapeutics Inc 6XC stockInsider Buying Signals & Low Entry Investment Plans - earlytimes.in
Soleno Therapeutics (NASDAQ:SLNO) Trading Down 9%Here's Why - MarketBeat
Soleno Therapeutics Inc Stock (SLNO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Soleno Therapeutics Inc Stock (SLNO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hirano Patricia C | SEE REMARKS |
Jul 01 '25 |
Sale |
82.76 |
3,830 |
316,971 |
13,206 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):